RC48-ADC in HER2-low Advanced Breast Cancer

Summary

To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) as salvage treatment in patients with HER2-low advanced breast cancer who have received up to one previous chemotherapy for recurrent or metastatic disease without previous use of antibody-drug conjugate.

Timeline

Start

2023-05-04

Primary completion

2026-12

Completion

2027-12

Drugs

Indications